| At Home By Enhance Therapies Llc | |
|
400 Nj-70, Unit 1, Lakewood, NJ 08701 | |
| (732) 987-3833 | |
| Not Available |
| Full Name | At Home By Enhance Therapies Llc |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 400 Nj-70, Lakewood, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124603246 | NPI | - | NPPES |
| Provider Name | Dora Sue Godnig |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164593752 PECOS PAC ID: 6305867896 Enrollment ID: I20051213000154 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Bridget A Delp |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669765996 PECOS PAC ID: 1254509128 Enrollment ID: I20110720000075 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Andrew D Chen |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699196121 PECOS PAC ID: 8224347174 Enrollment ID: I20151016000387 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Erin Mras |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972032787 PECOS PAC ID: 7416227954 Enrollment ID: I20170717002268 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Michael Johncola |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609440361 PECOS PAC ID: 5193120491 Enrollment ID: I20210825001518 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Kimberly Weyand |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154582815 PECOS PAC ID: 1456724111 Enrollment ID: I20230227003043 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Jessica Karros |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1194101782 PECOS PAC ID: 6709250483 Enrollment ID: I20230320002306 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Nancy Lee Colbaugh |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720213945 PECOS PAC ID: 1951769454 Enrollment ID: I20230615000315 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Karly Michelle Amato |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871847020 PECOS PAC ID: 9830550276 Enrollment ID: I20230801002373 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Anne Ruckdeschel |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1588934913 PECOS PAC ID: 3678934650 Enrollment ID: I20230808000066 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Provider Name | Kristen Pezzillo |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609659549 PECOS PAC ID: 6406210681 Enrollment ID: I20230907001512 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| At Home By Enhance Therapies Llc 400 Nj-70, Unit 1, Lakewood, NJ 08701 Ph: (732) 987-3833 | At Home By Enhance Therapies Llc 400 Nj-70, Unit 1, Lakewood, NJ 08701 Ph: (732) 987-3833 |
News Archive
In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.
There are 1.2 million Australians currently living with a communication disability, which can affect relationships, employment, education and social inclusion.
› Verified 1 days ago
Karen Tinana, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 282d Cedarbridge Ave, Lakewood, NJ 08701 Phone: 732-987-5122 | |
Mr. Kenneth Pavlinec, PT, CERT. MDT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 870 River Ave, Lakewood, NJ 08701 Phone: 732-886-9900 Fax: 732-886-9948 | |
Kathy Yoffe, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 35 Kelm Woods Ave, Lakewood, NJ 08701 Phone: 732-942-8348 | |
Dr. Rachel Kalish, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 153 Seminole Dr, Lakewood, NJ 08701 Phone: 845-641-8836 | |
Jennifer Kurak, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 761 River Ave, Suite D, Lakewood, NJ 08701 Phone: 732-833-3723 Fax: 888-247-4390 | |
Eikev Rehab Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1539 Rockaway Rd, Lakewood, NJ 08701 Phone: 347-439-8641 Fax: 732-377-5140 | |
Miss Maria Calabro, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1400 Route 70, Lakewood, NJ 08701 Phone: 732-370-0444 |